A Study of BGM0504 in Participants With Obesity

Sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Study ID
NCT06911203
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • BGM0504 — DRUG
    Administered SC
  • Tirzepatide — DRUG
    Administered SC

Study Details

To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.

Key Dates

Start date
Apr 3, 2025
Status verified
Jan 2025
Primary completion
Jan 11, 2026
Completion
Jan 11, 2026

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: BGM0504
    Participants will receive BGM0504 subcutaneously(SC).
  • Active Comparator: Tirzepatide
    Paritcipants will receive tirzepatide SC.

Primary Outcome Measure

Change From Baseline in Body Weight [ Time Frame: Week 0, Week 26 ]

Central Contacts

Related Studies